UNSPSC 51384631: Phenazone salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H12N2O.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F558OJK9JG. European Medicines Agency schedules phenazone salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03735MIG. The term phenazone salicylate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule phenazone salicylate under HS 29331190. SMILES: CC1CC(=O)N(N1C)C2CCCCC2.C1CCC(C(C1)C(=O)O)O.

UNSPSC 51384631 Phenazone salicylate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The three most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceuticals through cooperative purchasing—none of which are phenazone-specific products. State and local governments are using this code to solicit pain relievers, opioid-reversal agents, and broad pharmaceutical supply agreements rather than the salicylate compound the code nominally describes, signaling either misclassification in the source systems or a code that has drifted from its intended scope. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local jurisdictions). The geographic spread spans Florida, Texas, Minnesota, and Oregon, with the cooperative vehicle indicating multi-jurisdictional reach across participating states.

Recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (1,900 units annually, due July 26, 2023), the Texas HHS Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription programs (posted April 3, 2026), and Minnesota's MMCAP generic multi-source pharmaceutical and OTC RFP (due March 26, 2026, effective July 1, 2026). The MMCAP vehicle is the most developed procurement, requiring manufacturer pricing for identified NDC codes through three authorized wholesalers, cGMP and DSCSA compliance, and a 3 percent administrative fee. The code's recent activity reflects state and local demand for pharmaceutical products delivered through wholesalers and cooperative channels rather than phenazone compounds specifically, making this category a poor fit for vendors focused on salicylate products unless they supply broader pharmaceutical portfolios.